Since joining the company in 2006, Peter has been a major contributor to the growth of MedImmune. He has overseen the development of the global marketing and portfolio organizations, as well as managing the broader commercial, corporate development and strategy functions. He has also been accountable for MedImmune Ventures, a corporate development investment group.  In addition to being a member of the MedImmune Executive Team, Peter has led the cross-functional Brand Management Team and been a member of the Product Development Committee.

Greenleaf stated: “I am very excited about the future of MedImmune – and the role that biologics will play in achieving AstraZeneca’s long term success. I look forward to working closely with my colleagues from across the broader company.”

Prior to MedImmune, Greenleaf was at Centocor, Inc., where he served as franchise vice president, responsible for sales, marketing, strategic planning and business development. Previously, he served in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc. He has a bachelor of science degree from Western Connecticut State University and a master’s degree in business administration from St. Joseph’s University.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune’s website at www.medimmune.com

MedImmune is the wholly owned biologics business for AstraZeneca PLC. In addition to MedImmune, Mr. Zook is also responsible for AstraZeneca’s U.S. and Canadian businesses, as well as AstraZeneca’s Global Marketing organization.

“I am pleased to continue working with the leadership team here at MedImmune to advance our strategic plan to discover, develop and deliver innovative biologic treatments that can positively impact patient health,” stated Tony Zook.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at www.medimmune.com.

SOURCE MedImmune

CONTACT: Jamie Lacey of MedImmune, +1-301-398-4035, laceyj@medimmune.com

“It is imperative that we have strong leaders who can channel the continued growth of our product portfolio, particularly as we seek to build out the organization globally,” said David M. Mott, chief executive officer and president. “Jacqui, Lorin, Beth, E-J and Reg have the innate talent, industry experience and drive for results that will contribute to MedImmune’s continued leadership in biologics.”

Based at MedImmune’s Cambridge, UK site, Ms. Jacqueline Hall is accountable for the strategic leadership of global product development teams that are responsible for the generation and execution of development plans for biologics products. She joined Cambridge Antibody Technology (CAT), now MedImmune, in 2006 as vice president, project management. Previously, Ms. Hall served as project leader at GlaxoSmithKline where she was responsible for the strategic development of product candidates from selection through to market launch. She has also held positions at SmithKline Beecham, Pharmaco-LSR and Schering-Plough. Ms. Hall has a first-class honors degree in chemistry from Imperial College of Science and Technology/Birbeck College, London and a diploma in clinical science from the Welsh School of Pharmacy, Cardiff.

Dr. Lorin Roskos is responsible for managing and integrating preclinical and clinical PK/PD and bioanalytical groups at MedImmune sites in Maryland, California and England. Dr. Roskos became part of the MedImmune team in 2008 after a year at AstraZeneca as executive director of research and development. Prior to AstraZeneca, Dr. Roskos spent six years at Abgenix, Inc., as the head of PK and toxicology, and has prior experience in PK and drug metabolism at Amgen and Eli Lilly. He holds a doctorate in pharmaceutics from the University of Washington and a bachelor’s degree in biochemistry and pharmacy from the University of Georgia.

Ms. Beth Wensley oversees the global project management team that provides strategic project management in driving forward the product development teams and the overall product development portfolio. Ms. Wensley joined MedImmune in 2001, and has previously served as senior director, California operations; director, supply chain operations; and associate director, project management. She earned extensive project management, operational, manufacturing and environmental, health & safety experience during her tenure with companies such as Incyte Genomics, Raychem Corporation and Syntex Pharmaceuticals. She holds a master’s degree in business administration from Santa Clara University and a master’s in environmental science from the University of Washington. She also has a bachelor’s degree in biology from California Lutheran College and is APICS certified from the Association for Operations Management.

Based in the Netherlands as MedImmune’s new vice president, international regulatory affairs, vaccines, Dr. Erik-Jan Dekker is leveraging his 17 years’ experience in regulatory affairs to lead MedImmune’s expansion overseas. In his previous position at Baxter Healthcare, he was the global senior director, regulatory affairs, biologics, responsible for worldwide vaccine and biosurgery marketing authorization applications. Prior to joining Baxter Healthcare, Dr. Dekker was the director of regulatory affairs globally at Laboratoire Francais du Fractionnement et des Biotechnologies in France. Earlier in his career, Dr. Dekker held teaching positions at the University of Utrecht and Alkwin College. From the University of Utrecht, Dr. Dekker holds a doctorate in biochemistry and molecular developmental biology and genetics, a master’s degree in biology and international patent law and a bachelor’s degree in biology and geography.

As MedImmune’s new vice president, global strategic marketing and portfolio management, Dr. Reginald Seeto is responsible for providing strategic guidance on investment decisions and managing commercialization efforts for new products in various stages of development. In his previous position at Organon International, he was the vice president of global marketing, fertility, immunology, oncology and vaccines. Previously, Dr. Seeto was the executive director of marketing at Boehringer Ingelheim Pharmaceuticals and had served as an engagement manager at McKinsey & Company. He holds both a medical degree and a bachelor of science degree from the University of Sydney, and practiced medicine in Australia early in his career.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

 SOURCE MedImmune -0- 05/06/2008 /CONTACT: Media, Jamie Lacey, +1-301-398-4035, or Investors, Peter Vozzo, +1-301-398-4358, both of MedImmune/ /Web site: http://www.medimmune.com / (AZN) CO: MedImmune; AstraZeneca plc ST: Maryland, England, Netherlands IN: BIO MTC HEA SU: PER DS-KS -- NETU091 -- 9726 05/06/2008 09:34 EDT http://www.prnewswire.com 

GAITHERSBURG, Md., Dec. 20 /PRNewswire-FirstCall/ — Continuing the solidification of its role as the global biologics unit for AstraZeneca plc (AZ), MedImmune today announced that Andrew D. Skibo has joined the company as senior vice president, engineering and JoAnn Suzich, Ph.D., a 19-year veteran of the company, has been promoted to vice president, research and development, infectious disease. In addition, MedImmune announced that it has established a new site leadership team at its Cambridge facilities as a part of the plan to integrate the former Cambridge Antibody Technology (CAT) organization into AZ’s new global biologics unit, functioning under the name MedImmune.

“As MedImmune supports AZ in its efforts to build a major international presence in the research, development and manufacture of biological therapeutics, it’s critical that we continue to expand the depth of our leadership capabilities,” said David M. Mott, chief executive officer and president. “I am pleased with the high-caliber scientific and technical talent MedImmune continues to hire and retain as we strive to create the most productive and successful biotech business, with benefits to patients, shareholders and employees worldwide.”

New Leadership

Andrew D. Skibo joins MedImmune as senior vice president, engineering. In this role he will be responsible for overseeing large-scale capital projects at all of MedImmune’s facilities, including sites in California, Pennsylvania, Maryland, the Netherlands and the UK as well as the ongoing construction of the company’s antibody-manufacturing facilities in Frederick, Maryland. He reports to Bernardus Machielse, Drs., executive vice president, operations. Previously, Mr. Skibo held the position of vice president, corporate engineering and capital projects at Amgen, Inc., responsible for restructuring and rebuilding the corporate engineering function on a global level. Before joining Amgen, Mr. Skibo served in engineering management positions focused on pharmaceuticals and bioscience at Skanska, Inc; Foster Wheeler Corp.; Life Sciences International, Inc.; A.D. Skibo & Associates, Inc.; and Genentech, Inc. Mr. Skibo holds a master of science degree in chemical engineering with a specialty in biomedical engineering and a bachelor of science degree in organic chemistry, both from Massachusetts Institute of Technology.

Management Promotion

As vice president, infectious disease research, Dr. Suzich is responsible for overseeing MedImmune’s research in the development of antibodies and antibody-like molecules for the prophylaxis and treatment of infectious disease. Since joining MedImmune in 1988 in the role of scientist, she has held several positions of increasing responsibility, most recently as senior director, infectious disease research. During her tenure with the company she has been involved in many key development programs, including Synagis(R) (palivizumab) and the virus-like particle technology that is the basis of the new human papillomavirus (HPV) vaccines used to prevent cervical cancer. Dr. Suzich holds a doctorate in biochemistry from Purdue University and graduated magna cum laude with a bachelor of science degree in biology from Susquehanna University.

New Cambridge Site Leadership Team

MedImmune also announced today that following the integration of CAT into MedImmune, several personnel were appointed to the new Cambridge site leadership team under the guidance of John Stageman, Ph.D., vice president and interim site head.

Dr. Stageman has nearly 30 years of experience in R&D management throughout AZ and its predecessor companies, having pioneered large-scale biotechnology process development and scale-up at the start of his career. He entered the pharmaceutical business in 1993 rising through a number of senior roles in both drug discovery and development project management. In 1996, Dr. Stageman led the team that initiated the successful Phase 3 development of Faslodex(R) (fulvestrant). Later, as AZ vice president of biopharmaceutical strategy, he established a team that steered the organization’s aggressive drive into biologics, including the acquisitions of both CAT and MedImmune. Dr. Stageman has served on several UK Research Council grant committees and recently served as a member of the Royal Society working party on pharmacogenetics. He is an honorary professor at the University of Manchester and holds both a bachelor of science degree in chemistry and a doctorate in physical chemistry from the University of Bristol.

Jon Green, vice president, business operations is responsible for developing and maintaining all operational, infrastructure and support activities at MedImmune’s Cambridge site. Prior to joining CAT in 1992, he held a number of academic posts including on the Medical Research Council, Carshalton, and in the Department of Biochemistry at Imperial College London. Mr. Green holds a primary certification and a master’s degree, both in molecular biology. He is a fellow of the Institute of Biology with chartered status.

With 14 years of experience at CAT, Jane Osbourn, Ph.D., currently serves as vice president, research, and acting head, oncology research for MedImmune’s Cambridge operations. Previously, she has held a number of product and technology development posts within the organization. Dr. Osbourn completed a doctorate at the John Innes Centre for Plant Science Research in Norwich, followed by a British Heart Foundation Post doctoral fellowship at the Department of Medicine at Addenbrooke’s Hospital in Cambridge. She obtained a first-class degree in natural sciences (biochemistry) from the University of Cambridge.

Paul Varley, Ph.D., currently vice president, development, Cambridge, joined CAT in 1998 as director of pharmaceutical sciences and was promoted to vice president of biopharmaceutical development in 2004. Previously, Dr. Varley was head of protein science at British Biotech from 1993-1998 and had served as a staff scientist at the National Institute of Biological Standards and Control, UK. He has also undertaken post-doctoral research at the University of Newcastle upon Tyne and at the U.S. National Institutes of Health. Dr. Varley holds a degree in biomolecular sciences from Portsmouth Polytechnic and a doctorate from the University of Newcastle upon Tyne.

Andy Williams, Ph.D., vice president, research, project management joined CAT in 1993 following a post-doctoral fellowship at University of British Columbia in Vancouver in which he had continued the work on the molecular genetics of color vision he had initiated while pursuing his doctorate at Queen Mary and Westfield College, University of London. Dr. Williams has led a number of drug discovery and technology development projects at CAT while previously serving as head of target validation and later establishing the project management and planning group within drug discovery. He holds a first degree in biochemistry from Kings College, University of London.

Trevor Boulding, director, human resources (HR), joined CAT in January 2005 after many years of senior-level HR experience in hi-tech manufacturing and broadcasting. Under his direction, the organization in Cambridge has revised its employee performance management and remuneration systems, implemented a flexible benefits scheme and met the resourcing needs of the plan for biologics growth. Mr. Boulding holds a bachelor’s degree in Spanish and French from Birmingham University and is a member of the Institute of Personnel Management (now the Chartered Institute of Personnel & Development).

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

SOURCE MedImmune

CONTACT: Media: Jamie Lacey, +1-301-398-4035, or Investors: Peter Vozzo, +1-301-398-4358, both of MedImmune

“As MedImmune transitions into its new role as the global biologics unit of AstraZeneca, it is imperative to strengthen the company’s leadership platform across all facets of our business. Alex, Tim Hahn and Tim Maines add an additional depth of expertise in the areas of clinical research, antibody manufacturing, and quality assurance, respectively, which are each critical to our ability to deliver new drugs to patients in need,” said David M. Mott, chief executive officer and president. “The new vice presidential appointments of Max, Jonathan, Tim Pearson and Paul foster MedImmune’s ability to continue to recruit and grow talent, protect our intellectual properties, manage our financial reporting obligations to AstraZeneca plc (our parent company) and serve our customers to the highest possible standards.”

New Leadership

As the newest senior addition, Dr. Alexander Zukiwski joins MedImmune as senior vice president, clinical research, where he will be responsible for shaping and overseeing the company’s strategy for clinical trials of its drug candidates. Prior to joining the company, Dr. Zukiwski held several roles of increasing responsibility in support of Johnson & Johnson’s (J&J) medical affairs and clinical development functions at Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD); Centocor R&D; and Ortho Biotech, including therapeutic area head for oncology and acting head of oncology research & development. Most recently he held the position of vice president, head of clinical oncology, responsible for strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for J&JPRD and Centocor’s oncology development group. Before joining J&J, Dr. Zukiwski served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski holds degrees in pharmacy and medicine from the University of Alberta and the University of Calgary. He conducted his post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio, and the University of Texas M.D. Anderson Cancer Center. In his new role at MedImmune, Dr. Zukiwski will report to Ed Connor, M.D., executive vice president, clinical development and chief medical officer.

Also joining MedImmune is Dr. Timothy J. Hahn, who comes to his role as vice president, antibody manufacturing, building upon his more than 15 years experience in cell culture and live virus vaccine manufacturing with Merck & Co. In his position at MedImmune, he will be responsible for the antibody manufacturing strategy, including overall operations at MedImmune’s cell culture manufacturing facility currently under construction in Frederick, Maryland, as well as existing sites in Frederick and Nijmegen, Netherlands. Dr. Hahn received both his doctorate and master of science degrees in chemical engineering from Stanford University and his bachelor of science degree from Lehigh University.

Timothy J. Maines brings to MedImmune more than 20 years of pharmaceutical, medical device and biologics industry experience as a microbiologist and quality professional. In his role as vice president, corporate quality assurance, he will be responsible for fortifying world-class quality systems to improve the infrastructure of quality assurance operations in support of future growth, for ensuring the company’s products meet corporate and government standards and that quality assurance activities comply with applicable regulations, and for providing enhanced expertise and guidance in interpreting government regulations and guidelines. He most recently held positions at GTC Biotherapeutics (formerly known as Genzyme Transgenics Corporation), where he served as vice president of corporate quality, and Stryker Corporation, where he was director of quality assurance. Mr. Maines holds a bachelor of science degree in biology/microbiology from Gannon University.

Management Promotions

As vice president, human resources (HR), Mr. Max Donley is responsible for providing business-integrated leadership and delivering professional tools, programs and services to optimize MedImmune’s human capital investments through the HR function across all sites to drive business results. Prior to joining MedImmune in 2000 as a senior manager, he led field HR and development at Bed Bath & Beyond. Mr. Donley, a certified senior professional in human resources through the Society for Human Resource Management, holds a master and a bachelor degree in business administration from George Mason University and the University of Michigan, respectively.

Mr. Jonathan Klein-Evans now serves as vice president, intellectual property, overseeing all intellectual property issues for the company. Throughout his nearly 15 years in the field, Mr. Klein-Evans has worked on all aspects of patent law, including prosecution, litigation, opinions, interferences, oppositions and licensing. He joined MedImmune in 2002 as director, intellectual property. Previously, Mr. Klein-Evans was an in-house patent attorney at Human Genome Sciences, Inc. (HGS). Prior to his tenure at HGS, Mr. Klein-Evans worked for the law firm of Pennie & Edmonds, LLP, first as a law clerk, then a patent agent, and finally as a patent attorney over a course of six years. Mr. Klein-Evans holds a juris doctorate degree from Georgetown University Law Center; a master of science degree in biological sciences from Stanford University; and a bachelor of arts degree in biochemistry from Columbia University.

Mr. Tim Pearson was previously vice president, finance, and treasurer, and has been named chief financial officer, responsible for overseeing the company’s financial and accounting obligations. Since joining MedImmune in 1998, Mr. Pearson has raised more than $1.6 billion in debt throughout the course of his tenure, and served as corporate secretary from 2000-2004. Previously, Mr. Pearson worked at Integrated Health Services, Inc., most recently as assistant treasurer; at CIGNA Insurance as treasury manager; and at First National Bank of Maryland as a commercial lending officer. He holds a master of science degree in finance from Loyola College; a bachelor of science degree in accounting from the University of Maryland; and a bachelor of science degree in business administration from the University of Delaware.

Mr. Paul Williams was promoted to vice president, sales operations, and is now responsible for overseeing market research and marketing operations as well as for managing core sales operations competencies. Prior to joining MedImmune, Mr. Williams was a senior director at Centocor, Inc., guiding trade sales, customer supply chain and channel strategy. Mr. Williams holds a bachelor of science degree in finance from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Media, Jamie Lacey, +1-301-398-4035, or Investors, Peter Vozzo, +1-301-398-4358, both of MedImmune, Inc.

Caption: Cambridge Antibody Technology changes its name to MedImmune – the name of the U.S. biotech company that AstraZeneca PLC acquired for $15.6B in June 2007. (PRNewsFoto/MedImmune, Inc.)

Members of the media may download the photo at no charge from the following online archives:

– NewsCom: http://www.newscom.com/cgi-bin/prnh/20071029/NEM073
– AP Archive Topic Gallery: http://photoarchive.ap.org

This photo is also available via the AP PhotoExpress Network, as PRN13.

For more information on the photo, or on gaining access to the archives, media may contact the PR Newswire Photo Desk at photodesk@prnewswire.com .

SOURCE MedImmune, Inc.

“The new MedImmune is now the operationally independent and strategically aligned biologics business unit of AstraZeneca,” said David M. Mott, MedImmune president and chief executive officer. “Bringing together the biologics expertise of CAT, MedImmune and AstraZeneca allows us to preserve MedImmune’s traditional biotech agility and entrepreneurial spirit while encouraging strategic collaboration and cross fertilization of ideas under AstraZeneca’s world-class research umbrella.”

As part of the integration, John Stageman, Ph.D., vice president of AstraZeneca biopharmaceutical strategic planning, assumes the role of interim site head in Cambridge. Dr. Stageman commented, “AstraZeneca’s biologics capabilities have been enhanced significantly by the acquisitions of CAT and MedImmune to create a more robust, highly competitive and fully integrated biotechnology business. The scientific, technical and medical expertise that this team brings together is world class in discovering, developing, manufacturing and commercializing biopharmaceutical products.”

AstraZeneca acquired CAT, a biopharmaceutical company committed to developing human monoclonal antibody therapeutics, in June 2006 with the intent to have biologics account for 25-percent of its product pipeline by 2010. In 2007, AstraZeneca accelerated achievement of this biologics strategy through the successful acquisition of MedImmune, a fully integrated biotechnology company and one of the world’s ten largest within the industry,

About the New MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune’s website at http://www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Jamie Lacey, USA, of MedImmune, Inc., +1-301-398-4035

GAITHERSBURG, Md., April 2 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) today announced that it has promoted three senior leaders within its research and development (R&D) and medical organizations. The new executive appointments include Iksung Cho, vice president, biostatistics; Anthony J. Coyle, Ph.D., vice president, R&D, and head, inflammation and autoimmunity research; and Barbara White, M.D., vice president, clinical development, inflammatory disease.

“As MedImmune drives progress through its pipeline, the company relies on a growing number of senior leaders to contribute their expertise strategically,” said David M. Mott, chief executive officer and president. “Iksung’s statistical contributions have been critical in ensuring that we have solid Phase 3 pivotal data in support of our near-to-market infectious disease product candidates. Similarly, Anthony and Barbara have used their depth of experience and knowledge to advance important programs within our growing inflammatory disease portfolio.”

In his new role as vice president, biostatistics, Iksung Cho manages a team of nearly 20 statisticians who conduct activities such as clinical trial design and analysis for MedImmune’s research, development, clinical, regulatory and manufacturing organizations. He joined Aviron in 1997 as the primary statistician for the company’s influenza vaccine program. MedImmune completed the acquisition of Aviron in 2002. Previously, Mr. Cho had worked at Merck Research Laboratories within the vaccines development group. He holds masters of science degrees in mathematics and statistics from Virginia Polytechnic Institute & State University and has completed additional graduate-level coursework at Virginia Polytechnic & State University and Temple University. Mr. Cho is also the co-author of approximately 30 manuscripts or abstracts on vaccines and statistics.

As vice president, research and development, and head, inflammation and autoimmunity research, Anthony J. Coyle, Ph.D., oversees MedImmune’s preclinical research in disease areas such as asthma, lupus, rheumatoid arthritis and sepsis. Prior to joining MedImmune as a senior director in 2005, Dr. Coyle served as director, inflammation biology, at Millennium Pharmaceuticals in Cambridge, Massachusetts. In addition, he worked as a research scientist in the immunology department at the Glaxo Institute for Molecular Biology in Geneva, Switzerland. He also has more than six years of experience as a post-doctoral research assistant in immunology and pharmacology at Institut Pasteur in Paris and the National Jewish Center of Immunology in Denver. Dr. Coyle is a member of the American Thoracic Society and has published more than 120 scientific papers. He earned his bachelor of science and doctoral degrees in pharmacology from Kings College of the University of London.

Barbara White, M.D., now serves as vice president, clinical development, inflammatory disease. She joined MedImmune in January 2006 as senior director, and was appointed head of the inflammatory disease group in clinical development in November 2006. Prior to joining MedImmune, Dr. White was a director of medical affairs, inflammation therapeutic area, at Amgen where her activities included leading non-registration internal and external clinical research programs. Prior to 2003, Dr. White served as professor of medicine in the division of rheumatology, department of medicine, at the University of Maryland School of Medicine. She was formerly associate chief of staff of the research service at the Baltimore Veteran Administration (VA) Medical Center, one of the largest VA-based research programs in the country, where her research focused on immune-mediated mechanisms of lung fibrosis in scleroderma. Dr. White also previously served as co-director of the Johns Hopkins University and University of Maryland Scleroderma Center. She has been active in the American College of Rheumatology, serving as chair of the research committee and as a member of the board of directors, and has served as an ad hoc member of the FDA Arthritis Advisory Committee. She has served on the editorial boards of Arthritis & Rheumatism and Arthritis Care and Research and has been a reviewer for numerous journals and grant review panels. Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board certified in Internal Medicine, Rheumatology and Allergy/Clinical Immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Media, Kate Barrett, +1-301-398-4320, or Investors, Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.

Mr. Hotz joined Houlihan Lokey Howard & Zukin in 2002 and is currently the firm’s co-chairman, co-head of corporate finance, and senior managing director. He is also a member of Houlihan Lokey’s board of directors and the operating committee. Previously, he was senior vice chairman of UBS and head of corporate finance for the Americas. In 1991, he joined a predecessor firm to UBS (Dillon, Read & Co. Inc.) as co-head of the corporate finance department and as a member of the firm’s operating committee and board of directors. Currently, Mr. Hotz serves on the boards of two other public companies: Universal Health Services, Inc. and PepBoys. He is a graduate of Rutgers University and received his MBA from Cornell University.

Mr. Hotz replaces Gordon Macklin on MedImmune’s board of directors. Mr. Macklin died in February 2007.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Media, Jamie Lacey, +1-301-398-4035, or Investors, Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.

“Jamie and Mark bring a depth of experience and knowledge that we expect to be critically instrumental in helping us achieve our long-term growth goals for our respiratory syncytial virus (RSV) franchise,” said David M. Mott, chief executive officer and president. “They join a dedicated management team, passionate about creating value for shareholders, new medical options for patients and healthcare providers, and rewarding careers for employees.”

In his new role as vice president, infectious disease marketing, Jamie Harrell is responsible for leading the strategic direction of marketing activities for Synagis(R) (palivizumab) as well as the commercialization of MedImmune’s next-generation monoclonal antibody for RSV. Prior to joining MedImmune, Mr. Harrell was senior director, marketing and global market development at Centocor, Inc. In this role, he was responsible for supporting the growth of Centocor’s anti-TNF monoclonal antibody in ex-U.S. markets in conjunction with Schering Plough. Mr. Harrell joined Centocor in 1999 and held positions of increasing responsibility, including senior director, marketing, rheumatology franchise, and associate director, marketing, for Centocor’s cardiovascular business unit. Prior to Centocor, he held positions at Searle Pharmaceuticals and Rhone-Poulenc Rorer. Mr. Harrell holds a bachelor’s degree in administration with a double major in marketing and economics from Samford University.

As MedImmune’s new vice president, managed markets, Mark Stanton is leveraging his 12 years of managed care experience to build and lead MedImmune’s integrated strategy to support all products in the managed care market. In his previous position at Endo Pharmaceuticals, he was the director, corporate accounts, responsible for the development of national managed market activities, including managed care organizations, pharmacy benefit management and group purchasing organizations. Prior to joining Endo, Mr. Stanton held positions of increasing responsibility at Serono, Inc., leading to director, managed care and contracting. Earlier in his career, Mr. Stanton held sales and marketing positions at the Rhone-Poulenc Group and the Boehringer Mannheim Corporation. Mr. Stanton holds a bachelor’s degree in business administration from Castleton State College.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Media: Clarencia Stephen, +1-301-398-4073, or Investors: Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.